The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder

Heil, Jessica; Zajic, Stefan; Albertson, Emily; Brangan, Andrew; Jones, Iris; Roberts, Wendy; Sabia, Michael; Bodofsky, Elliot; Resch, Alissa M.; Rafeq, Rachel; Haroz, Rachel; Buono, Russell J.; Ferraro, Thomas N.; Scheinfeldt, Laura B.; Salzman, Matthew; Baston, Kaitlan

doi:10.1186/s12920-020-00837-3

Cited by 3 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GOALS and OPTIN are prospective, observational studies that include the collection of self-reported demographic and perception survey data at enrollment. In addition, participants are asked to grant access to their electronic health records for up to five years prior to baseline enrollment and up to 12 months after baseline enrollment [1].…”

Section: Methodsmentioning

confidence: 99%

“…CORI study enrollment criteria consist of an age of at least 18 years, English language proficiency, written informed consent, willingness to provide a saliva sample for DNA analysis, and either in-treatment status for chronic pain at Cooper University Health Care clinic (OPTIN) or in-treatment status for opioid use disorder at the Center for Healing at Cooper University Health Care as defined by DSM-5 (GOALS) [1].…”

Section: Study Populationsmentioning

confidence: 99%

“…The Camden Opioid Research Initiative (CORI) is a multi-armed research study [1] consisting of a chronic pain cohort (Optimizing Pain Treatment in New Jersey (OPTIN)), an opioid use disorder (OUD) cohort (Genomics of Opioid Addiction Longitudinal Study (GOALS)), and a biobank resource of biospecimens collected from individuals who have died from an opioid overdose (CORI Biobank). As part of this initiative, we investigated the potential utility of pharmacogenetics (PGx) to inform opioid medication management in two clinical settings in the city of Camden: chronic pain management and opioid use disorder management.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Populationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies are currently underway to understand the genetic factors that may influence treatment-related outcomes among patients receiving MOUD. For example, The Genomics of Opioid Addiction Longitudinal Study (GOALS) will be a prospective observational study of 400 patients receiving MOUD that will help determine the interplay between genetic and non-genetic (e.g., depression, anxiety, adverse childhood experiences) factors on key treatment outcomes (e.g., treatment retention rate, toxicology results, overdoses) 51 . While conducted with typically smaller patient cohorts, neuroimaging studies can provide a vast amount of data per patient.…”

Section: Genomics and Neuroimagingmentioning

confidence: 99%

“…For example, The Genomics of Opioid Addiction Longitudinal Study (GOALS) will be a prospective observational study of 400 patients receiving MOUD that will help determine the interplay between genetic and non-genetic (e.g., depression, anxiety, adverse childhood experiences) factors on key treatment outcomes (e.g., treatment retention rate, toxicology results, overdoses). 51 While conducted with typically smaller patient cohorts, neuroimaging studies can provide a vast amount of data per patient. For example, a recent systematic review of functional magnetic resonance imaging studies found that persons with OUD display heightened neural activation to heroin cues, and this pattern is attenuated by MOUD, predicts treatment response, and is reduced after extended abstinence.…”

Section: Genomics and Neuroimagingmentioning

confidence: 99%

Using Data Science to Improve Outcomes for Persons with Opioid use Disorder

et al. 2022

View full text Add to dashboard Cite

Medication treatment for opioid use disorder (MOUD) is an effective evidence-based therapy for decreasing opioid-related adverse outcomes. Effective strategies for retaining persons on MOUD, an essential step to improving outcomes, are needed as roughly half of all persons initiating MOUD discontinue within a year. Data science may be valuable and promising for improving MOUD retention by using “big data” (e.g., electronic health record data, claims data mobile/sensor data, social media data) and specific machine learning techniques (e.g., predictive modeling, natural language processing, reinforcement learning) to individualize patient care. Maximizing the utility of data science to improve MOUD retention requires a three-pronged approach: (1) increasing funding for data science research for OUD, (2) integrating data from multiple sources including treatment for OUD and general medical care as well as data not specific to medical care (e.g., mobile, sensor, and social media data), and (3) applying multiple data science approaches with integrated big data to provide insights and optimize advances in the OUD and overall addiction fields.

show abstract

Postmortem toxicology findings from the Camden Opioid Research Initiative

Kusic,

Heil,

Zajic

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

The United States continues to be impacted by decades of an opioid misuse epidemic, worsened by the COVID-19 pandemic and by the growing prevalence of highly potent synthetic opioids (HPSO) such as fentanyl. In instances of a toxicity event, first-response administration of reversal medications such as naloxone can be insufficient to fully counteract the effects of HPSO, particularly when there is co-occurring substance use. In an effort to characterize and study this multi-faceted problem, the Camden Opioid Research Initiative (CORI) has been formed. The CORI study has collected and analyzed post-mortem toxicology data from 42 cases of decedents who expired from opioid-related toxicity in the South New Jersey region to characterize substance use profiles. Co-occurring substance use, whether by intent or through possible contamination of the illicit opioid supply, is pervasive among deaths due to opioid toxicity, and evidence of medication-assisted treatment is scarce. Nearly all (98%) of the toxicology cases show the presence of the HPSO, fentanyl, and very few (7%) results detected evidence of medication-assisted treatment for opioid use disorder, such as buprenorphine or methadone, at the time of death. The opioid toxicity reversal drug, naloxone, was detected in 19% of cases, but 100% of cases expressed one or more stimulants, and sedatives including xylazine were detected in 48% of cases. These results showing complex substance use profiles indicate that efforts at mitigating the opioid misuse epidemic must address the complications presented by co-occurring stimulant and other substance use, and reduce barriers to and stigmas of seeking effective medication-assisted treatments.

show abstract

The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder

Cited by 3 publications

References 42 publications

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Using Data Science to Improve Outcomes for Persons with Opioid use Disorder

Postmortem toxicology findings from the Camden Opioid Research Initiative

Contact Info

Product

Resources

About